Gerstmann-Straussler-Scheinker syndrome

Gerstmann-Sträussler-Scheinker syndrome (GSS) is an extremely rare, inherited prion disease — a type of transmissible spongiform encephalopathy — caused by pathogenic variants in the PRNP gene, which encodes the prion protein. It belongs to the same family of diseases as Creutzfeldt-Jakob disease and fatal familial insomnia. GSS primarily affects the central nervous system, leading to progressive neurodegeneration characterized by the accumulation of abnormal prion protein in the brain, particularly the cerebellum. The hallmark clinical features of GSS include progressive cerebellar ataxia (difficulty with coordination and balance), dysarthria (slurred speech), and cognitive decline that may progress to dementia. Patients often initially present with gait unsteadiness and clumsiness in midlife, typically between the ages of 40 and 60, though onset can vary. Additional symptoms may include nystagmus, spastic paraparesis, extrapyramidal signs such as parkinsonian features, and peripheral neuropathy. The disease progresses over several years, with the average duration from symptom onset to death ranging from approximately 2 to 10 years, which is generally slower than classic Creutzfeldt-Jakob disease. There is currently no cure or disease-modifying treatment for Gerstmann-Sträussler-Scheinker syndrome. Management is entirely supportive and symptomatic, focusing on maintaining quality of life, managing pain, addressing mobility issues, and providing psychological support for patients and families. Genetic counseling is strongly recommended for affected families given the autosomal dominant inheritance pattern. Research into anti-prion therapies is ongoing but no effective intervention has yet been established for clinical use.

Common questions about Gerstmann-Straussler-Scheinker syndrome